MediWound Ltd (F:M8W) — Market Cap & Net Worth
Market Cap & Net Worth: MediWound Ltd (M8W)
MediWound Ltd (F:M8W) has a market capitalization of $171.29 Million (€146.52 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #17236 globally and #1616 in its home market, demonstrating a -1.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MediWound Ltd's stock price €11.40 by its total outstanding shares 12852255 (12.85 Million). Also see MediWound Ltd asset portfolio for a full breakdown of the balance sheet.
MediWound Ltd Market Cap History: 2015 to 2026
MediWound Ltd's market capitalization history from 2015 to 2026. Data shows growth from $116.04 Million to $171.29 Million (4.93% CAGR). Also see MediWound Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
MediWound Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MediWound Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check M8W live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
13.91x
MediWound Ltd's market cap is 13.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $70.14 Million | $1.56 Million | -$18.89 Million | 45.02x | N/A |
| 2017 | $54.53 Million | $2.50 Million | -$22.15 Million | 21.85x | N/A |
| 2018 | $50.94 Million | $3.40 Million | -$1.06 Million | 14.98x | N/A |
| 2019 | $39.07 Million | $31.79 Million | $4.96 Million | 1.23x | 7.88x |
| 2020 | $46.58 Million | $21.76 Million | -$9.20 Million | 2.14x | N/A |
| 2021 | $29.75 Million | $23.76 Million | -$13.55 Million | 1.25x | N/A |
| 2022 | $181.81 Million | $26.50 Million | -$19.60 Million | 6.86x | N/A |
| 2023 | $135.23 Million | $18.69 Million | -$6.72 Million | 7.24x | N/A |
| 2024 | $250.93 Million | $20.22 Million | -$30.22 Million | 12.41x | N/A |
| 2025 | $235.90 Million | $16.96 Million | -$23.88 Million | 13.91x | N/A |
Competitor Companies of M8W by Market Capitalization
Companies near MediWound Ltd in the global market cap rankings as of September 20, 2026. Review MediWound Ltd tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to MediWound Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
MediWound Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, MediWound Ltd's market cap moved from $116.04 Million to $ 171.29 Million, with a yearly change of 4.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €171.29 Million | -27.39% |
| 2025 | €235.90 Million | -5.99% |
| 2024 | €250.93 Million | +85.56% |
| 2023 | €135.23 Million | -25.62% |
| 2022 | €181.81 Million | +511.11% |
| 2021 | €29.75 Million | -36.13% |
| 2020 | €46.58 Million | +19.23% |
| 2019 | €39.07 Million | -23.30% |
| 2018 | €50.94 Million | -6.59% |
| 2017 | €54.53 Million | -22.26% |
| 2016 | €70.14 Million | -39.56% |
| 2015 | €116.04 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of MediWound Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $171.29 Million USD |
| MoneyControl | $171.29 Million USD |
| MarketWatch | $171.29 Million USD |
| marketcap.company | $171.29 Million USD |
| Reuters | $171.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn cen… Read more